Instil Bio financials
$7.14+1.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$78.6M | -$73.5M | -$159.2M | -$226.5M | -$155.6M |
| Net income | -$71.4M | -$74.1M | -$156.1M | -$223.2M | -$156.8M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-10.70 | $-11.39 | $-24.00 | $-34.46 | $-29.60 |
| EBITDA | -$61.4M | -$62.4M | -$82.4M | -$197.3M | -$152.8M |
| Operating cash flow | -$36.6M | -$55.7M | -$78.6M | -$180.2M | -$122.4M |
| Free cash flow | -$36.6M | -$55.7M | -$99.3M | -$264.8M | -$180.3M |
| Diluted shares | 6.7M | 6.5M | 6.5M | 6.5M | 5.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.6M | $8.8M | $9.2M | $43.7M | $37.6M |
| Short-term investments | $69.5M | $104.5M | $141.2M | $217.2M | $416.5M |
| Total debt | $84.8M | $84.2M | $81.4M | $72.3M | $0.00 |
| Total assets | $203.5M | $263.6M | $325.6M | $482.1M | $610.0M |
| Total liabilities | $89.7M | $94.1M | $99.8M | $118.5M | $54.8M |
| Shareholders' equity | $113.9M | $169.4M | $225.8M | $363.6M | $555.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology